Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities is a complete reference on possible drug development targets to be leveraged in therapeutic developments. Covering both signaling pathways and specific proteins, the book presents ways to modulate the molecular and cellular alterations observed in metabolic diseases and disorders through the application of new or classical drugs. The comprehensive coverage starts by providing an overview of metabolic diseases and disorders, biological alterations, and pharmacological targets. This section covers targets at both molecular, and subcellular and cellular levels. The next section in the book is focused on pharmaceutical targeting of organs, including a dedicated chapter to the gut-brain axis. Next comes a thorough review of the current advances in metabolic syndrome research. Section VI is focused on inborn errors of metabolism and is followed by a section devoted to natural molecules and their pharmacological potential to treat these conditions. The Editor introduces next a whole section dedicated to the role of the microbiota in metabolic diseases therapeutics. The following sections cover the impact of aging, nanotechnology, the environment, and finally diagnostic techniques in metabolic diseases and disorders. Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities meet the needs of pharmacology researchers looking for a comprehensive and authoritative source of information on possible therapeutic targets to treat these conditions. Research physicians, nutritionists, pharmacists, and biologists can benefit from the detailed information provided at the different levels of targets identified to treat metabolic diseases and conditions. - Covers the most prevalent metabolic diseases and disorders such as metabolic syndrome, diabetes mellitus (types I and II) and dyslipidemia, among others- Includes chapters on the microbiome and environmental pollution as they relate to metabolic diseases and conditions- Discusses cellular structures like the endoplasmic reticulum and mitochondria as pharmacological targets
